Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

100.0%

3 terminated/withdrawn out of 3 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

2 of 0 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1
2(66.7%)
Phase 2
1(33.3%)
3Total
Phase 1(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04032847Phase 1Terminated

ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC

Role: lead

NCT03997474Phase 1Terminated

ATL001 in Patients With Metastatic or Recurrent Melanoma

Role: lead

NCT04785365Phase 2Terminated

Long-Term Follow-Up Study of Patients Receiving ATL001

Role: lead

All 3 trials loaded